Trevor FITZPATRICK

iEnvision commercial team

[Trevor FITZPATRICK @fitzpat01]

Congratulations @90TEN winning Communiqué Communications Consultancy of the Year 2nd year running! Well done #cxhealth for excellent virtual format. Off for some real bubbles

[Communiqué @CxHealth]

The final award of the night, sponsored by @aurorahealthpr, is the Communiqué Communications Consultancy of the Year. The award-winning agency is @90TEN – well done! #cxhealth https://t.co/YdGgAN5CKT

[Trevor FITZPATRICK @fitzpat01]

#CxHealth @CxHealth Communique first virtual awards are about to kick-off. Good luck everyone. Especially rooting for our friends and colleagues at 90TEN!

[Trevor FITZPATRICK @fitzpat01]

Encouraging to see drug developers and regulators include systematic, meaningful patient input in all phases of development.

[Envision Pharma Group @EnvisionPharma]

Strong support for #patient role in research planning and publications at the Managed Access event hosted by @CBI_Conferences. Check out our Plain Language Summaries Publications Toolkit https://t.co/BZUait8OqF #GPP4 #ENVISION

[Trevor FITZPATRICK @fitzpat01]

Thanks @CBI_Conferences for a great meeting in Amsterdam. Excellent speakers and plenty of practical ideas to take forward with patient groups, industry and EU/national regulators.

[Envision Pharma Group @EnvisionPharma]

The Managed Access event hosted by @CBI_Conferences highlighted the value to pharma of efficient management systems #iEnvision integrates the process end-to-end. https://t.co/yzaEsgFVOR

[Trevor FITZPATRICK @fitzpat01]

Seminal article. Peter Oborne was a strong Brexiteer. Here IMO he offers some level headed common sense https://t.co/enyZzgtcbT

[Envision Pharma Group @EnvisionPharma]

Drop by our booth at #eyeforpharma in Barcelona & find out about our range of #medicalaffairs services & software https://t.co/BKYUH8SWKI

[Trevor FITZPATRICK @fitzpat01]

Envision HEOR writers make complex science relevant to non-specialist audiences. http://t.co/y6ojuAak3l https://t.co/t3mramJBoL

[Envision Pharma Group @EnvisionPharma]

#ISPORPhila R&D is shifting to diseases that matter to patients and payers - but the science is more difficult